ROIVANT SCIENCES LTD. Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest
ROIVANT SCIENCES LTD. (ROIV) reported Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest of -$98.14 million for the 12-month period ending 2026-03-31, per its 10-K filed 2026-05-20.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity · last filed 2026-05-20
- ROIVANT SCIENCES LTD. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2026 was -$98.14M.
- ROIVANT SCIENCES LTD. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2025 was -$184.60M.
- ROIVANT SCIENCES LTD. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2024 was -$116.35M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 12 month |
|---|---|
| 2026-03-31 | -$98.14M 10-K · filed 2026-05-20 |
| 2025-03-31 | -$184.60M 10-K · filed 2026-05-20 |
| 2024-03-31 | -$116.35M 10-K · filed 2026-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |